TECH stock · BIO stock · Lician Pro · $19.99/mo or $149/yr
TECH vs BIO · rev $1.22B vs P/E 43, rev $2.58B
Bio-Techne Corp (TECH) versus Bio-Rad Laboratories (BIO) — a side-by-side from cached financials, not a winner call.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Bio-Rad Laboratories (BIO) common stock.
Latest reported TECH revenue for 2026-06-30 was $1.22B. Net income was $181.9M. Revenue was down 0.4% from 2025-06-30 to 2026-06-30. TECH currently screens at market cap $8.49B.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. BIO currently screens at trailing P/E 43.1.
TECH currently screens at market cap $8.49B. BIO currently screens at trailing P/E 43.1.
Not investment advice. Open the TECH and BIO stock pages for the full models.
Basic comparison
Price, market cap, and trailing P/E stay on this page.
| Metric | TECH | BIO |
|---|---|---|
| Price | $72.57 | $353.70 |
| Market cap | $8.49B | — |
| Trailing P/E | — | 43.1 |
Deeper peer metrics
Net income and multi-year revenue growth are the peek. More peer metrics open below. This block stops at the labels.
| Metric | TECH | BIO |
|---|---|---|
| Net income | Pro | Pro |
| Revenue growth | Pro | Pro |
More peer metrics
Operating margin, EPS, free cash flow, and gross margin are on Pro.
TECH vs BIO comparison FAQ
What is TECH's market cap?
Bio-Techne Corp (TECH) currently screens at market cap $8.49B.
What is BIO's P/E ratio?
Bio-Rad Laboratories (BIO) screens at trailing P/E 43.1.
What is TECH's latest revenue?
Latest reported TECH revenue for 2026-06-30 was $1.22B.
What is BIO's latest revenue?
Latest reported BIO revenue for 2025-12-31 was $2.58B.
What is TECH's net income?
Net income was $181.9M for Bio-Techne Corp (TECH).
What is BIO's net income?
Net income was $759.9M for Bio-Rad Laboratories (BIO).
How did TECH revenue change on this page?
Revenue was down 0.4% from 2025-06-30 to 2026-06-30.
Where is the TECH vs BIO comparison listed?
The cached TECH vs BIO comparison is listed at https://lician.com/compare/tech-vs-bio.
Not investment advice.